Bitdeer Technologies Group vs Cassava Sciences Inc — how do they compare? Bitdeer Technologies Group trades at $12.38 (market cap $3.01B), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Bitdeer Technologies Group is far larger — about 57.2× Cassava Sciences Inc's market cap, and Bitdeer Technologies Group is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| BTDR | FLNA | |
|---|---|---|
Market Cap | $3.01B | $52.66M |
Sector | Technology | Health |
52-Week High | $25.90 | $4.64 |
52-Week Low | $7.28 | $1.09 |
Enterprise Value | $4.77B | -$33.92M |
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $12.13, down 8.73% over 24 hours, with technical indicators signaling a bearish trend. The stock shows strong analyst support with 9 out of 11 ratings as Buy and a consensus price target of $23.40, but fundamentals reveal challenges: negative net income margin of -26.96% and three consecutive quarterly earnings misses. Recent news highlights expansion into AI infrastructure, including a new $36 million manufacturing facility in Nevada and an AI cloud platform award in June 2026.
The outlook is mixed: bullish analyst sentiment and strategic growth in AI and mining infrastructure offer upside potential, but persistent losses, negative cash flow from operations, and high debt-to-asset ratio of 35.69% pose significant risks. Investors should weigh the company's expansion against its financial health and sector volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →